The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population

March 13, 2023 updated by: Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University

Preventive and Personalized Medicine (2021-2023)

This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Kazakhstan
      • Almaty, Kazakhstan, 050020
        • Kazakhstan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

KAZAKH POPULATION

Description

Inclusion Criteria:

  • Persons of Kazakh nationality
  • Age up to 59 years inclusive at the time of primary myocardial infarction
  • Myocardial infarction was established in accordance with the EOC criteria: An increase and / or decrease in the level of cardiac troponin must be combined with at least one of the following: • Symptoms of myocardial ischemia • Newly occurring ischemic changes on the ECG • The appearance of a pathological Q wave • Identification according to imaging data methods of new areas of non-viable myocardium, or new areas of local contractility disorders of presumably ischemic etiology • Detection of a thrombus in the coronary arteries according to coronary angiography
  • Presence of coronary angiography
  • Persons able and willing to provide written informed consent;

Exclusion Criteria:

  • Age at primary myocardial infarction 60 years and older
  • Heart defects, congenital and acquired
  • Non-ischemic cardiomyopathies
  • Autoimmune diseases
  • Diabetes mellitus at the time of development of primary myocardial infarction
  • Terminal stages of renal and hepatic failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental group:
Patients with Heart Attack
Genetic: DNA analysis
GWAS
Control group
Patients without Heart Attack
Genetic: DNA analysis
GWAS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of SNPs associated with Heart Attack
Time Frame: 1 year
Using GWAS to identify candidate genes associate with Heart Attack
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asfendiyarov Kazakh National Medical University

Investigators

  • Study Director: Aisulu Mussagaliyeva, PhD, Research Institute of Cardiology and Internal Medicine
  • Study Director: Roza Kuanyshbekova, Research Institute of Cardiology and Internal Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2021

Primary Completion (Actual)

January 20, 2023

Study Completion (Actual)

January 20, 2023

Study Registration Dates

First Submitted

September 25, 2021

First Submitted That Met QC Criteria

October 21, 2021

First Posted (Actual)

October 25, 2021

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1187

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Attack

Clinical Trials on DNA analysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe